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Carmem Lisboa5, Maria Montes de Oca6, Carlos Tálamo6, Bartolomé Celli7, Oliver A Nascimento1, Mariana R Gazzotti1 and
José R Jardim1 for the PLATINO Team
BACKGROUND: Spirometry is the gold standard for diagnosing chronic obstructive pulmonary disease (COPD). Although there are
a number of different guideline criteria for deciding who should be selected for spirometric screening, to date it is not known which
criteria are the best based on sensitivity and speciﬁcity.
AIMS: Firstly, to evaluate the proportion of subjects in the PLATINO Study that would be recommended for spirometry testing
according to Global initiative for Obstructive Lung Disease (GOLD)-modiﬁed, American College of Chest Physicians (ACCP), National
Lung Health Education Program (NLHEP), GOLD and American Thoracic Society/European Respiratory Society (ATS/ERS) criteria.
Secondly, we aimed to compare the sensitivity, speciﬁcity, and positive predictive and negative predictive values, of these ﬁve
different criteria.
METHODS: Data from the PLATINO study included information on respiratory symptoms, smoking and previous spirometry testing.
The GOLD-modiﬁed spirometry indication criteria are based on three positive answers out of ﬁve questions: the presence of cough,
phlegm in the morning, dyspnoea, age over 40 years and smoking status.
RESULTS: Data from 5,315 subjects were reviewed. Fewer people had an indication for spirometry (41.3%) according to the
GOLD-modiﬁed criteria, and more people had an indication for spirometry (80.4%) by the GOLD and ATS/ERS criteria. A low
percentage had previously had spirometry performed: GOLD-modiﬁed (14.5%); ACCP (13.2%); NLHEP (12.6%); and GOLD and
ATS/ERS (12.3%). The GOLD-modiﬁed criteria showed the least sensitivity (54.9) and the highest speciﬁcity (61.0) for detecting
COPD, whereas GOLD and ATS/ERS criteria showed the highest sensitivity (87.9) and the least speciﬁcity (20.8).
CONCLUSION: There is a considerable difference in the indication for spirometry according to the ﬁve different guideline criteria.
The GOLD-modiﬁed criteria recruit less people with the greatest sum of sensitivity and speciﬁcity.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a preventable
and treatable disease with some signiﬁcant extra-pulmonary
effects that may contribute to the severity of the disease. It is
characterised by persistent airﬂow limitation. The obstruction is
usually progressive and is associated with an increased chronic
inﬂammatory response to noxious particles or gases in the lung.1,2
Early diagnosis of COPD is based on symptoms, identiﬁcation
of risk factors and spirometry.1 The American College of Chest
Physicians (ACCP)3 recommends spirometry only for patients with
respiratory symptoms, especially dyspnoea, and states that
spirometry should not be performed in asymptomatic individuals,
even in those with known risk factors for COPD. The National Lung
Health Education Program (NLHEP)4 recommends that spirometry
should be considered in individuals over 45 years old with a
smoking history, or at any age in individuals with respiratory
symptoms. The Global initiative for Obstructive Lung Disease
(GOLD)1 guideline recommends spirometry in individuals over
40 years old who have been exposed to tobacco, with a family
history of chronic lung disease and/or any respiratory symptom.
The American Thoracic Society and European Respiratory Society
(ATS/ERS) guideline2 recommends spirometry in any individual
with respiratory symptoms and/or previous exposure to risk
factors for the disease.
However, only considering symptoms, or age above 40, or a
smoking history, as indicators for spirometry is likely to prove a
poor cost-effective strategy for population screening for COPD.
Post-nasal drip, asthma and gastroesophageal reﬂux are the most
common causes of chronic cough in immunocompetent non-
smoking individuals.5 Chronic cough may affect up to 40% of the
population.6 Nasal blockage, nasal secretion, sneezing, asthma,
cold air sensitivity and aspirin intolerance are also related to
cough.7 In addition, productive cough is one of the main
symptoms reported by patients with bronchiectasis.8 Dyspnoea,
another common respiratory symptom, varies based on beha-
vioural and physiologic responses. The main causes of dyspnoea
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are asthma, heart failure, myocardial ischaemia, COPD and
interstitial lung disease.9 Dyspnoea is also a symptom of anxiety,
especially in individuals with panic disorder or hyperventilation
syndrome.10 According to the PLATINO study, the prevalence of
smokers and ex-smokers aged 40 years or more was 57% in São
Paulo, 67% in Santiago, 44% in Mexico City, 57% in Montevideo
and 58.4% in Caracas.11 Similar results were found in London,
where 44.8% of the population above 35 years of age were
smokers or ex-smokers.12
The adoption of any of the above four guideline criteria seems
likely to be too non-speciﬁc, leading to a large number of
unnecessary spirometries. Our hypothesis is that the adoption of
more rigid criteria for spirometry could increase speciﬁcity,
decrease the number of unnecessary spirometries and make
spirometry screening more cost-effective. Based on modiﬁcation
of the GOLD criteria for spirometry, we believe that spirometry
would be more speciﬁc if performed in individuals with at least
three positive answers out of the ﬁve following questions: ‘Do you
cough most days?’; ‘Do you bring up phlegm in the morning?’; ‘Do
you walk at a slower pace than other people of the same age?’;
‘Are you older than 40 years?’; and ‘Are you a smoker or
ex-smoker?’. These are our ‘GOLD-modiﬁed’ criteria.
The objective of this study, therefore, was to evaluate the
proportion of individuals from the PLATINO study that met the
criteria for spirometry assessment based on GOLD-modiﬁed,
ACCP, NLHEP, GOLD and ATS/ERS guideline criteria, and to
evaluate the applicability of each of these guideline criteria for the
diagnosis of COPD as deﬁned by a forced expiratory volume in
1 s/forced vital capacity (FEV1/FVC) ratio below 0.7.
MATERIALS AND METHODS
Study design
This study was based on data from the Latin American Project for the
Investigation of Obstructive Lung Disease (PLATINO).11
The inclusion criteria were males and females aged 40 years or more
living in selected households of the metropolitan areas of São Paulo
(Brazil), Santiago (Chile), Mexico City (Mexico), Montevideo (Uruguay) and
Caracas (Venezuela). COPD was deﬁned as an FEV1/FVC ratio below 0.70.
The exclusion criteria were: institutionalised individuals; history of mental
illness; thoracic, abdominal or ophthalmic surgery in the past 3 months;
angina or myocardial infarction in the past 3 months; diagnosis of active
tuberculosis; pregnancy; and acute respiratory infection within 3 weeks
before the interview.
Respiratory symptoms, smoking and previous spirometry assessment
were evaluated using a questionnaire based on the following question-
naires: American Thoracic Society Division of Lung Diseases (ATS/DLD);13
European Community Respiratory Health Survey II (ECRHS II);14 Lung
Health Study (LHS);15 and Short Form 12.16
Equipment and techniques
Spirometry (Easy One; NDD; Medical Technologies, Switzerland) was
performed according to ATS guidelines17 and it was repeated after
15min of bronchodilator inhalation (salbutamol, 200 µg). The criteria for
COPD diagnosis was based on a post-bronchodilator FEV1/FVC ratio o0.70
(GOLD).1 The criteria for spirometry are shown in Table 1.
Statistical analysis
For the descriptive analysis, numerical data are shown as mean and
standard deviation. The categorical variables are presented in absolute
value and percentage. The t-test was used to compare numerical variables
between two independent groups. Categorical variables' proportions
between independent groups were compared using the Chi-squared test.
Analysis of variance was used for comparison of Latin American Cities.
P values o0.05 were considered statistically signiﬁcant.
RESULTS
Demographic data
From a total of 6,711 eligible subjects in all locations, 5,571
individuals completed questionnaires and 5,315 spirometry tests
were obtained. The mean age was 56.3 ± 11.7 years. The
proportion of women was higher (mean 60.5% of the total) and
the prevalence of smokers in the population was 29.8% (Table 2).
The COPD prevalence in Latin America was 14.3%.
Indication for spirometry assessment
According to our GOLD-modiﬁed criteria, 2,195 (41.3%) individuals
fulﬁlled the indication criteria for spirometry. There were 3,013
individuals (56.7%) who met the spirometry indication criteria
according to ACCP, 4,010 individuals (75.5%) according to NLHEP
and 4,273 (80.4%) according to GOLD and ATS/ERS (Table 3).
Table 4 shows the prevalence of spirometry indication in each of
the ﬁve cities.
Indication of spirometry for the diagnosis of COPD
In order to identify the most effective criteria for the screening of
COPD, we compared the number of individuals who met the
criteria for spirometry assessment according to GOLD-modiﬁed,
ACCP, NHLEP, GOLD and ATS/ERS and the presence or absence of
COPD diagnosis (Table 5). GOLD-modiﬁed had the lowest number
of individuals with indication for spirometry (41.3%). On the
contrary, GOLD and ATS/ERS criteria had the highest indication for
spirometry (80.4%).
The sensitivity, speciﬁcity, positive predictive (PPV) and negative
predictive values (NPV) for the COPD screening criteria are
presented in Table 6. The GOLD-modiﬁed criteria showed the
lowest sensitivity (54.9%)—i.e., the subjects with COPD that
were correctly identiﬁed, and the highest speciﬁcity (61%)—i.e.
the number of individuals without COPD who were identiﬁed
correctly. GOLD and ATS/ERS criteria showed the highest
sensitivity (87.9%) and the lowest speciﬁcity (20.8%).
The PPV and NPV analysis showed a small variability among the
different criteria. The PPV varied from 15.6% for the GOLD and
Table 1. Individuals classiﬁed as having indication for spirometry according to the various guideline criteria
GOLD-modiﬁed Three positive answers out of the following ﬁve questions: ‘Do you cough most days?’; ‘Do you bring up phlegm in the morning?’;
‘Do you walk at a slower pace than other people of the same age?’; ‘Are you older than 40 years?’; and ‘Are you a smoker or
ex-smoker?’
ACCP3 Individuals with respiratory symptoms, especially dyspnoea; spirometry should not be performed in asymptomatic individuals,
even in those with risk factors for COPD
NLHEP4 Individuals 45 years and older with a smoking history or individuals of any age with respiratory symptoms
GOLD1 Individuals over 40 years old, exposed to tobacco, with a family history of chronic lung disease and/or any respiratory symptom
ATS/ERS2 Individuals with respiratory symptoms and/or previous exposure to risk factors for the disease
GOLD1 and ATS/ERS2 were evaluated together as our study population was over 40 years of age.
Abbreviations: ACCP, American College of Chest Physicians; ATS/ERS, American Thoracic Society/European Respiratory Society; GOLD, Global initiative for
Obstructive Lung Disease; NLHEP, National Lung Health Education Program.
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ATS/ERS criteria to 19% for the GOLD-modiﬁed; the NPV varied
from 89% for the GOLD-modiﬁed to 91.2% for GOLD and ATS/ERS
criteria. Since NLHEP, GOLD and ATS/ERS criteria for spirometry
screening are very similar, with the only difference being the age
cut-off, the values for sensitivity, speciﬁcity, PPV and NPV were
also similar.
DISCUSSION
Main ﬁndings
Considering the high mortality and treatment costs of COPD, the
disease should be diagnosed in its early phases. Risk factors such
as tobacco smoking, exposure to air pollution (burning of wood), a
family history of COPD, or a history of recurrent respiratory
infections during childhood,18 should highlight the need for
screening and early intervention.19 Undiagnosed COPD is a
common problem and is usually associated with poor quality of
life and poor functional status.20 Spirometry is still the gold
standard for the diagnosis of COPD and it should be performed in
all individuals with clinical signs of the disease.1 Despite the
beneﬁts from early diagnosis, the results of this study show that
spirometry assessment is underused in Latin America.
Use of our GOLD-modiﬁed criteria (which consider the presence
of respiratory symptoms and risk factors) as an indication for
COPD screening was shown to be the most cost-effective method,
as it produced the lowest number of individuals requiring
evaluation and provided the highest proportion of COPD
diagnoses.
Interpretation of ﬁndings in relation to previously published work
Our results come from the database of the PLATINO study, which
was a cross-sectional, population-based study designed to
evaluate the prevalence and impact of COPD in the metropolitan
areas of ﬁve large cities in Latin America.11 However, the study
also offers the opportunity to evaluate the use of different criteria
for the early diagnosis of COPD and the relevance of these criteria.
Table 2. Demographic characteristics of PLATINO population
Total
N (%) 5,315
Age (years) 56.3± 11.7
Gender
M, n (%) 2,102 (39.5)
F, n (%) 3,213 (60.5)
BMI (kg/m2) 28.1± 5.5
Education (years) 7.6± 4.7
0–2 years, n (%) 667 (12.6)
3–4 years, n (%) 816 (15.4)
5–8 years, n (%) 1,803 (34.0)
⩾ 9 years, n (%) 2,021 (38.1)
Smoking status
Never, n (%) 2,262 (42.6)
Ex-smokers, n (%) 1,469 (27.6)
Smokers, n (%) 1,582 (29.8)
Smoking history (pack/years)
Ex-smokers 17.7 (24.7)
Smokers 19.1 (18.6)
Function test
FEV1/FVC 0.78± 0.08
FEV1 (l) 2.6± 0.8
FEV1 (%) 99.0± 18.6
FVC (l) 3.4± 0.9
FVC (%) 99.9± 16.4
COPD, n (%) 759 (14.3)
Numerical variables are shown as mean (s.d.).
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmon-
ary disease; F, female; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; M, male.
Table 3. Total number (n) and percentage (%) of participants with indication for spirometry according to the study criteria and number of
participants who performed spirometry before the PLATINO study (n= 5,313)
Indication for spirometry n= 5,313 Previous spirometry assessment n= 603 P
GOLD-modiﬁed, n (%) 2,195 (41.3) 319 (53.0) o0.001
ACCP, n (%) 3,013 (56.7) 396 (65.7) o0.001
NLHEP, n (%) 4,010 (75.5) 504 (83.6) o0.001
GOLD/ATS/ERS, n (%) 4,273 (80.4) 526 (87.2) o0.001
Abbreviations: ACCP, American College of Chest Physicians; ATS, American; Thoracic Society; ERS, European Respiratory Society; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; NLHEP, National Lung Health Education Program.
Table 4. Proportion of individuals who performed spirometry before PLATINO related to the number of individuals with indication for spirometry
according to the different criteria in the Latin American cities
São Paulo n= 961 Santiago n= 1,173 México City n= 1,000 Montevideo n= 885 Caracas n= 1,294
GOLD-modiﬁed
n= 2,195
42/345 (12.2) 126/628 (20.1) 31/354 (8.8) 55/333 (16.5) 65/535 (12.1)
ACCP
n= 3,013
51/469 (10.9) 148/758 (19.5) 46/591 (7.8) 75/463 (16.2) 76/732 (10.4)
NLHEP
n= 4,010
68/682 (10.0) 186/953 (19.5) 57/737 (7.7) 104/661 (15.7) 89/977 (9.1)
GOLD/ATS/ERS
n= 4,273
76/741 (10.3) 191/1,013 (18.9) 62/779 (8.0) 107/700 (15.3) 90/1,040 (8.7)
Abbreviations: ACCP, American College of Chest Physicians; ATS, American Thoracic Society; ERS, European Respiratory Society; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; NLHEP, National Lung Health Education Program.
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For early diagnosis, it is crucial to consider the cost-effectiveness
of,21 and the best criteria for,22 screening of individual subjects.
Despite world guidance, only 12–14% of individuals who met
the GOLD-modiﬁed, ACCP, NLHEP, GOLD and ATS/ERS criteria had
had spirometry assessment in the past. Our data conﬁrm that
spirometry is underused. As the presence of at least one symptom
is recommended in the GOLD-modiﬁed and ACCP criteria, the
absence of symptoms could be an explanation for the low rates of
spirometry assessment according to these criteria.23 Usually,
individuals believe that respiratory symptoms such as chronic
cough and sputum production are not important, and typically
they have been neglected by doctors for years.23 However, even
considering the more comprehensive criteria of NLHEP, GOLD and
ATS/ERS, which do not require the presence of respiratory
symptoms, the use of spirometry was low. According to GOLD-
modiﬁed and ACCP criteria, 41.3 and 56.7% of the study
population, respectively, had an indication for spirometry testing,
whereas the recommendation was higher with NLHEP and
GOLD/ATS/ERS—i.e., 75.5 and 80.4%, respectively.
The underutilisation of spirometry is not an isolated fact in Latin
America. In 1997, the epidemiological study IBERPOC (Estudio
Epidemiológico de EPOC en España)24 showed that only 16.5% of
diagnosed COPD patients had had previous spirometry. However,
a decade later, the EPI-SCAN study (Epidemiologic Study of COPD
in Spain)25 demonstrated that 58.5% of COPD patients had had
spirometry performed. An American study in primary care showed
that in a group of individuals identiﬁed as having potential risk
factors for COPD according to the GOLD and ATS/ERS criteria, only
50% had had previous spirometry.26 Even in developed countries,
the criteria for spirometry assessment are not followed, and the
criteria do not receive the attention needed for the diagnosis of
COPD. In Italy, a survey evaluating the use of spirometry for COPD
diagnosis among clinicians showed that 30% of doctors do not
use it.27 In Japan, a sample of general and specialist physicians
were provided with clinical cases and a survey regarding diagnosis
and treatment of COPD; the results showed that 81.9% of
physicians recommended a chest X-ray, 49.1% spirometry and
17.7% a computed tomography scan for the diagnosis of COPD.28
According to Soriano et al.,21 COPD could be prevented on
three levels: primary prevention, with modiﬁcation or reduction of
risk factors, specially smoking; secondary prevention, with screen-
ing and early detection of COPD; and tertiary prevention, with the
purpose of improving health status, decreasing or slowing disease
progression and reducing exacerbation rate. Spirometry has an
important role at all three preventive levels. The DIDASCO study
from Belgium showed a high accuracy with the use of a portable
spirometer by trained general practitioners and they were able to
incorporate spirometry into their clinical routine.29
Among the criteria considered in our study, our GOLD-modiﬁed
criteria showed the highest sum of sensitivity and speciﬁcity,
whereas the GOLD and ATS/ERS criteria had the lowest sensitivity
and speciﬁcity sum. This is an important ﬁnding, as the GOLD
criteria have been used worldwide for the diagnosis and
treatment of COPD patients. Isolated respiratory symptoms are a
poor indicator for COPD30—for example, one-third of the USA
population presents respiratory symptoms.31 A cohort study of
3,955 individuals in the USA showed that 83% reported at least
one respiratory symptom and 65% reported multiple respiratory
symptoms, and among the 2,917 smokers, 86% reported at least
one symptom and 70% had multiple symptoms.32 Another study
in Spain showed a low speciﬁcity for respiratory symptoms: 8.6%
of individuals with chronic cough, 6.2% with dyspnoea and 30.7%
with wheezing had normal spirometry, and among individuals
with restrictive disease 10.6% had cough, 17.2% had dyspnoea
and 45.5% had wheezing.33
Strengths and limitations of this study
Our study has some limitations. We used an FEV1/FVC ratio below
0.7 to deﬁne COPD, which decreases with age due to loss of lung
elasticity and recoil, resulting in overdiagnosis of COPD in the
elderly population.34 Nonetheless, this deﬁnition is currently the
most accepted one owing to its practicality and it has been used
in the majority of studies related to COPD prevalence published
lately.11,25 Another limitation was the utilisation of a self-reported
questionnaire for assessment of symptoms. The ideal would be a
more detailed and individualised evaluation as most individuals in
our population were lay people and they may not comprehend
the deﬁnition of symptoms.
Conclusions and implications for future research, policy and
practice
We conclude that criteria for spirometry screening for COPD that
only consider age or isolated symptoms have low speciﬁcity and
may require a higher number of spirometries to be performed.
Our GOLD-modiﬁed criteria may recruit a smaller proportion of
individuals for spirometry but they are the criteria with the largest
sum of sensitivity and speciﬁcity and the largest proportion of
COPD patients diagnosed. In addition to incentives for spirometry
performance in primary care practice, the insufﬁcient use of
spirometric testing for COPD detection shown in this study
suggests the need to implement more speciﬁc educational
Table 6. Sensitivity, speciﬁcity, PPV and NPV according to the
screening criteria for COPD
Se Sp PPV NPV
GOLD-modiﬁed 54.9 61.0 19.0 89.0
ACCP 67.3 45.1 17.0 89.2
NLHEP 85.9 26.3 16.3 91.8
GOLD/ ATS/ERS 87.9 20.8 15.6 91.2
Abbreviations: ACCP, American College of Chest Physicians; ATS, American
Thoracic Society; ERS, European Respiratory Society; GOLD, Global Initiative
for Chronic Obstructive Lung Disease; NLHEP, National Lung Health
Education Program; NPV, negative predictive value; PPV, positive predictive
value; Se, sensitivity; Sp, speciﬁcity.
Table 5. Number of participants with indication for spirometry
assessment for diagnosis of COPD according to modiﬁed GOLD
criteria, ACCP, NLHEP, GOLD and ATS/ERS in relation to total number of
participants (n= 5,315) and COPD diagnosis
Indication for spirometry
assessment
Total
(n= 5,315)
With COPD
(n=759)
P
GOLD-modiﬁed, n (%)
Yes 2,195 (41.3) 417 (59.9) o0.001
No 3,120 (58.7) 342 (45.1)
ACCP, n (%)
Yes 3,013 (56.7) 511 (67.3) o0.001
No 2,302 (43.3) 248 (32.7)
NLHEP, n (%)
Yes 4,010 (75.5) 652 (85.9) o0.001
No 1,305 (24.5) 107 (14.1)
GOLD/ATS/ERS, n (%)
Yes 4,273 (80.4) 667 (87.9.) o0.001
No 1,042 (19.6) 92 (12.1)
Abbreviations: ACCP, American College of Chest Physicians; ATS, American
Thoracic Society; ERS, European Respiratory Society; GOLD, Global Initiative
for Chronic Obstructive Lung Disease; NLHEP, National Lung Health
Education Program.
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programmes. Aditionally, it is necessary to increase the availability
of spirometry tests in primary care settings in order to increase the
chances of identifying COPD patients.
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